The underlying mechanism of high-dose therapy (HDT)-related oral mucositis (OM) may be partly mediated by alterations in the normal salivary composition. This study evaluated salivary antioxidant and immunological capacities observed in myeloma patients suffering from HDTrelated OM, and assessed potential contribution of these factors to OM development. Twenty-five consecutive myeloma patients treated with melphalan 200 mg/m 2 followed by autologous SCT were enrolled. Patients underwent a daily assessment for OM, and salivary samples were collected on days À3 and þ 7 of transplantation and analyzed for secretory IgA and antioxidant capacity. The degree of mucosal damage was assessed by measuring the salivary carbonyl and albumin (Alb) levels. OM, reported in 96% of patients, appeared to be most severe on 8 day after transplantation (range: þ 2 to þ 14). Clinical mucositis was associated with significant reduction in salivary secretory IgA (54%; P ¼ 0.05), and antioxidant activity, measured by total antioxidant status (40%; P ¼ 0.0004), antioxidant capacity (ImAnOx) (23%; P ¼ 0.002) and uric acid level (51%; P ¼ 0.006). The increase found in salivary Alb (119%; P ¼ 0.024) and carbonyl (28%; P ¼ 0.047) levels, indicates mucosal and oxidative damage, respectively. These salivary changes might enhance mucositis development and symptoms. Therapeutic interventions, enhancing antioxidative and immunological activities need to be investigated.
Introduction
High-dose melphalan (HDM), followed by autologous SCT, is the treatment of choice in the majority of younger patients with myeloma, providing an improved PFS and overall survival. 1, 2 This treatment, however, is often complicated by oral and gastrointestinal mucositis (90%), which results in severe mouth and throat pain and requires opioid analgesia. [3] [4] [5] [6] [7] [8] [9] Moreover, it is often associated with an increased risk of life-threatening infections and prolonged hospitalization. 10 The pathophysiology of high-dose therapy (HDT)-related oral mucositis (OM) appears to be a multi-step process. The initial damage to DNA leads to immediate death of submucosal (endothelial cells and fibroblasts) and epithelial cell. 11 Induced reactive oxygen species damage the DNA and cell membranes, triggering intracellular signaling pathways that result in mucosal injury. 11 Earlier studies have suggested the development of a 'hostile,' immunodeficient salivary milieu after HDT, enhancing the direct impact of HDT on submucosal and epithelial cells. 12, 13 However, there are almost no extensive studies investigating the precise role of salivary antioxidative mechanisms in overcoming the oxidative injury observed in HDT-related mucositis.
This study was designed to evaluate the changes in oral mucosa and salivary function, focusing on the antioxidant and immunological salivary capacities observed in myeloma patients receiving HDT followed by autologous SCT.
Materials and methods
This study was approved by the Institutional Review Board of both medical centers, and informed consent was obtained from all patients. Twenty-five consecutive myeloma patients, 16 males and 9 females, undergoing autologous SCT during the period from August 2005 to October 2006 were enrolled and completed the study. Patients undergoing a second autologous SCT were excluded (patient characteristics are presented in Table 1 ). Clinical assessment for OM was performed daily, starting on day À3 of transplantation (before HDT) and ending at patient discharge (at least 14 days after transplant). The evaluation included a daily questionnaire, estimating a subjective assessment of dryness of the mouth, need for plentiful drinking, difficulty in swallowing, burning sensation, changes in taste and halitosis. Physical examination was performed by two physicians, defining the severity of mucositis according to the WHO oral toxicity scale 14 and the complexity and color of the saliva.
Saliva collection
Saliva samples were collected at two time points: a day before high-dose therapy (day À3 of transplantation) and on day 7 after transplantation-the expected time for advanced mucositis. A third saliva sample was collected from eight patients on day 21 after transplantation-the time point of clinical improvement of mucositis Table 2 .
Saliva samples were collected following at least a 1-h fast. The participants were requested to drink 100 ml of water followed by mouthwash with fresh water. The patients were then asked to collect saliva in a tube over a period of up to 10 min without making any effort to increase their saliva secretion (that is, no sucking). Salivary flow rate values represent the volume of saliva secreted per minute. The saliva was transferred to polypropylene tubes and stored at À20 1C for further analysis.
Salivary biochemical analysis
The sialochemistry analysis was performed as previously described 15 and included evaluation of pH values and calcium (Ca), magnesium (Mg) and phosphate (P) concentrations, amylase and lactic dehydrogenase activities as well as total protein and total albumin (Alb) concentrations. Secretory IgA concentrations were measured by the radial-immunodiffusion method of Mancini et al., 16 using an Oxford viewer for measuring the diameters of precipitation rings; the square of the diameter of the ring formed was quantitatively related to the concentration of the salivary parameters analyzed by this method.
The salivary carbonyls were measured quantitatively using the NWK-PCK01 protein carbonyl ELISA kit (Northwest Life Science Specialties, LLC, Vancouver, WA, USA).
Salivary oxidative analysis
Antioxidant capacity. The total antioxidant capacity (ImAnOx) of the saliva was evaluated by ELISA colorimetric test (Immundiagnostik AG, Bensheim, Germany), measuring the reduction in the concentration of exogenously provided hydrogen peroxide following exposure to salivary antioxidants. The residual hydrogen peroxide was determined calorimetrically, performing an enzymatic reaction, which involves the conversion of tetramethylbenzidine to a colored product detected by microtiter plate reader at 450 nm. Quantification was performed by calibrator.
Total antioxidant status. The assay utilizes a commercial kit supplied by Randox Laboratories (Crumlin, County Antrim, UK), in which metmyoglobin is transformed into ferrylmyoglobin in the presence of iron. Incubation of the latter with the Randox reagent-ABTS results in the formation of a radical having a blue-green color, which can be detected at 600 nm.
Uric acid concentration. Concentration of uric acid (UA) was measured with a kit supplied by Sentinel CH (Milano, Italy). In this assay, UA is transformed by uricase into allantoin and hydrogen peroxide, which under the catalytic influence of peroxidase, oxidizes the chromogen (4-aminophenazone/N-ethyl-methylanilin propan-sulphonate sodic) to form a red compound.
Peroxidase activity. The salivary peroxidase activity was measured according to the NBS assay. 17 Briefly, the colorimetric change induced by the reaction between the enzyme and the substrate, dithiobis 2-nitrobensoic acid, in the presence of mercaptoetanol, is read at 412 nm wave length for 25 s.
Superoxide dismutase activity. Total salivary activity of the superoxide dismutase (SOD) enzyme (Cu/Zn-and Mn-SOD) was measured using the xanthine oxidase/XTT method as previously described. 18 The method is a modification of the NBT assay in which XTT is reduced by superoxide anion that is generated by xanthine oxidase. Formazan is read at 470 nm. The SOD enzyme inhibits the reaction by scavenging the superoxide anion. One unit of the enzyme is defined as the amount of enzyme needed for 50% inhibition of the absorption.
Statistical analysis
Frequencies and percentages were calculated for categorical variables. Categorical variables were analyzed by FisherIrwin exact test. Differences in saliva parameters were evaluated by Kruskal-Wallis test (a multiple-comparison non-parametric test) and between pairs of subgroups by two-sample Wilcoxon rank-sum test (non-parametric). The correlation between saliva parameter values and patient's complaints were analyzed by Spearman correlation test.
Results

Pre(D-3) and peri(D þ 7)-transplant assessment
Clinical and laboratory characteristics of OM. Oral mucositis, resulting in various degrees of oral discomfort, was recorded in 96% of patients (32% with mucositis grade X2). Mucositis-related signs were initially observed on days 2-10 (median; day 6) and were most severe on day 8 after transplantation (range: day þ 2 to þ 14).
The incidence of mucositis-related symptoms was significantly higher on day 7 post transplantation compared with 'pre-HDT' assessment; dry mouth sensation was reported by 80 vs 24% of patients, whereas burning sensation, change in taste, halitosis and difficulty to swallow were reported in 72, 92, 48 and 61% of patients, respectively, compared with none pre-HDT (Po0.0001 for all).
Salivary flow rate. There was no statistically significant change in the salivary flow rate between days À3 and þ 7 of transplantation (mean salivary flow rate was 0.15 vs 0.16 ml/min, respectively). The majority (84%) of the saliva samples collected pre-HDT (day À3) were clear compared with 52% of the samples collected on day þ 7 (P ¼ 0.032). The remaining samples (48%) were frothy, sticky or colored and thus defined as unclear.
Salivary composition. Various compositional alterations were noted in the saliva samples obtained pre-(day À3) vs post-(day þ 7) HDT. Salivary pH was significantly higher in the pre-HDT samples (pH: 6.7 vs 5.8, a 14% reduction, P ¼ 0.0008). Conversely, saliva concentrations of Ca, Mg and Alb were significantly greater on day þ 7-date of maximal severity of mucositis (Ca: 5.3 vs 2.55 mg per 100 ml, þ 101%, P ¼ 0.004; Mg: 1.7 vs 0.95 mg per 100 ml, þ 79%, P ¼ 0.02; Alb: 101.4 vs 46.3 mg/l, þ 119%, P ¼ 0.02; Figure 1 ).
There were no significant differences in the levels of lactic dehydrogenase, total protein, phosphor and amylase measured on days À3 and þ 7.
Analysis of salivary immunological and antioxidative capacities. Secretory IgA level was significantly lower on day þ 7 (190 vs 89 mg/ml, a 57.2% reduction, P ¼ 0.05; Figure 2a) .
The antioxidant activity, reflected by ImAnOx, total antioxidant status (TAS) and UA level, was significantly reduced on day þ 7 after transplants compared with day À3 (Figure 2b (Figure 2b ). The concentrations of salivary antioxidative enzymes; peroxidase and superoxide dismutase tended to be higher in the post-HDT samples: þ 14% (P ¼ 0.05) and þ 15% (P ¼ 0.23), respectively.
Oxidatively damaged salivary proteins were significantly higher on day þ 7 compared with day À3 (salivary carbonyls increased by 28%, P ¼ 0.047) (Figure 3 ).
Correlation between salivary alterations and oral sensorial complaints. Data analysis revealed correlation between various oral sensorial complaints and the immunological and antioxidant activity of saliva.
The change in taste tended to be associated with a decrease in ImAnOx (Spearman correlation factors: SCF; À0.45, P ¼ 0.05) and IgA levels (SCF:À0.40, P ¼ 0.08), whereas dry mouth sensation was mainly associated with an increased carbonyl level (SCF: À0.45, P ¼ 0.06).
Day þ 21-clinical and laboratory assessment All patients reported a significant improvement in oral discomfort by day þ 21 post transplant. The severity of oral pain significantly decreased (1 of 8 patients who could be evaluated compared with 18 of 25 on day þ 7); however; dry mouth sensation and abnormal taste sensation remained common (5 of 8 and 6 of 8, respectively).
Secretory IgA level was still significantly lower than pre-HDT, but higher than observed on day þ 7 (102 mg/ml). Antioxidant activities returned into normal values (ImAnOx: 268.9 mmol/l; TAS-0.58 mmol/l; UA: 2.85 mg per 100 ml), but were still lower than those measured pre-HDT.
A similar tendency with partial return to pre-transplant values was noted for concentrations of Alb: 75.6 mg/l, Ca: 3.95 mg per 100 ml and Mg: 1.25 mg per 100 ml.
Discussion
This study presents a longitudinal clinical and laboratory overview of the development of HDT-related OM, showing the correlation between sensorial symptoms, physical examination and altered salivary immunological and antioxidative capacities evolving during mucositis.
Oral mucositis is known to cause significant discomfort, oral pain and difficulty in swallowing liquids and food, and its marked incidence, approaching 40-90% in patients treated with HDM, has been previously reported. 9, [19] [20] [21] A recent study, examining the incidence and severity of OM in myeloma patients treated with melphalan at a dose of 140 mg/m 2 , reported OM in 90% of patients (including grades 3-4 in 46%), most severely on day 12 post transplantation. The severity of OM mainly depended on the melphalan dosage per kilogram and body weight. 9 The early onset of mucositis observed in our study (median day þ 6) most probably reflects a higher melphalan dose (200 mg/m 2 compared with 140 mg/m 2 , þ 43%) applied.
The pathogenesis of mucositis is mainly related to chemotherapy induced epithelial and submucosal cell apoptosis, resulting in generation of reactive oxygen species that enhance mucosal cell injury and blood vessel disintegrity. 5, 22 Interestingly, there are almost no data regarding the potential capacity of local salivary antioxidative mechanisms in overcoming the evolving oxidative damage. 5 The significant increase observed in salivary carbonyl levels ( þ 28%, P ¼ 0.047) reflects profound oxidative damage to salivary proteins, 23, 24 which may result in protein and enzyme dysfunction. The salivary antioxidant capacity measured on day þ 7 (ImAnOx., TAS and UA) appears to be low (24-51% reduction compared with pre-HDT levels, Po0.01) and insufficient to overcome this oxidative flood. However, the concentrations of all antioxidants measured 2 weeks later (day þ 21) were normal, suggesting a compensatory production of antioxidative molecules, evoked in response to severe mucosal destruction. The 'unexpected' marginally increased levels of the antioxidant peroxides and SOD observed on day þ 7, also reported by other investigators, 25 may reflect the beginning of this unsuccessful compensatory process.
Another salivary player that may facilitate mucositisrelated symptoms is the immunodeficient salivary environment observed following HDT. Similar to earlier studies 13, 26 we observed a significant decrease in salivary secretory IgA level, which may promote bacterial growth and enhance mucosal ulcerations.
The increased concentrations of salivary Ca, Mg and Alb, observed following HDT, may promote the development of significant mucosal disintegrity, allowing penetration of various substances from the blood into the oral cavity and thus deteriorating mucosal damage even further. 15 Of interest, mucositis-related symptoms were most prominent in the presence of impaired mucosal antioxidant and immunological defense systems.
This study has shown that 'salivary milieu' developed following HDT is hostile to the oral mucosa and is most likely to exacerbate chemotherapy-induced mucosal damage and delay its repair. The salivary antioxidant molecules fail to overcome the HDT-related oxidative damage, the local immunological defense system is impaired and the excessive penetration of various substances due to blood vessel disintegrity, may all promote mucosal injury and mucositis-related symptoms.
The data obtained in this study suggest that targeted therapies, improving salivary components and function (for example, anti-oxidative agents), need to be seriously investigated in the clinical post-HDT setting to further ameliorate often debilitating OM.
